AbbVie has announced plans to acquire Apogee Therapeutics in a $10.9 billion all-cash transaction, according to company statements and Wall Street Journal reporting. The deal remains subject to regulatory review and standard closing conditions. Limited sourcing from two outlets, one left-center and one unrated, restricts perspective diversity on the transaction.